Cargando…

Temporal trends in initiation of VKA, rivaroxaban, apixaban and dabigatran for the treatment of venous thromboembolism - A Danish nationwide cohort study

Danish nationwide registries were used to investigate temporal trends in initiation of rivaroxaban or apixaban or dabigatran versus vitamin K antagonists (VKA) in patients with venous thromboembolism (VTE). Patients treated with one of the NOACs (rivaroxaban, dabigatran, apixaban) or VKA were identi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sindet-Pedersen, Caroline, Pallisgaard, Jannik Langtved, Staerk, Laila, Berger, Jeffrey S., Lamberts, Morten, Torp-Pedersen, Christian, Gislason, Gunnar H., Olesen, Jonas Bjerring
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5469820/ https://www.ncbi.nlm.nih.gov/pubmed/28611403 http://dx.doi.org/10.1038/s41598-017-03596-x

Ejemplares similares

Risk of Ischemic Stroke, Hemorrhagic Stroke, Bleeding, and Death in Patients Switching from Vitamin K Antagonist to Dabigatran after an Ablation
por: Pallisgaard, Jannik Langtved, et al.
Publicado: (2016)

Familial Clustering of Venous Thromboembolism – A Danish Nationwide Cohort Study
por: Sindet-Pedersen, Caroline, et al.
Publicado: (2016)

Cardioversion and Risk of Adverse Events with Dabigatran versus Warfarin—A Nationwide Cohort Study
por: Pallisgaard, Jannik Langtved, et al.
Publicado: (2015)

Non-vitamin K antagonist oral anticoagulation usage according to age among patients with atrial fibrillation: Temporal trends 2011–2015 in Denmark
por: Staerk, Laila, et al.
Publicado: (2016)

Comparison of the Non-VKA Oral Anticoagulants Apixaban, Dabigatran, and Rivaroxaban in the Extended Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis
por: Cohen, A. T., et al.
Publicado: (2016)

Correction: Comparison of the Non-VKA Oral Anticoagulants Apixaban, Dabigatran, and Rivaroxaban in the Extended Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis
por: Cohen, A. T., et al.
Publicado: (2016)

Dabigatran use in Danish atrial fibrillation patients in 2011: a nationwide study
por: Sørensen, Rikke, et al.
Publicado: (2013)

Comparative thromboembolic risk in atrial fibrillation with and without a secondary precipitant—Danish nationwide cohort study
por: Gundlund, A, et al.
Publicado: (2019)

Cardiovascular and non-cardiovascular hospital admissions associated with atrial fibrillation: a Danish nationwide, retrospective cohort study
por: Christiansen, Christine Benn, et al.
Publicado: (2013)

Major Bleeding Complications and Persistence With Oral Anticoagulation in Non‐Valvular Atrial Fibrillation: Contemporary Findings in Real‐Life Danish Patients
por: Lamberts, Morten, et al.
Publicado: (2017)

Psoriasis Carries an Increased Risk of Venous Thromboembolism: A Danish Nationwide Cohort Study
por: Ahlehoff, Ole, et al.
Publicado: (2011)

Risk factors and a 3-month risk score for predicting pacemaker implantation in patients with atrial fibrillation
por: Dalgaard, Frederik, et al.
Publicado: (2020)

Risk and timing of venous thromboembolism in patients with gastrointestinal cancer: a nationwide Danish cohort study
por: Tønnesen, Jacob, et al.
Publicado: (2023)

Evaluation of the Determination of Dabigatran, Rivaroxaban, and Apixaban in Lupus Anticoagulant-Positive Patients
por: Úlehlová, Jana, et al.
Publicado: (2021)

Real-world cost-effectiveness of rivaroxaban and apixaban vs VKA in stroke prevention in non-valvular atrial fibrillation in the UK
por: Bowrin, Kevin, et al.
Publicado: (2020)

Non-vitamin K antagonist oral anticoagulants vs. vitamin-K antagonists in patients with atrial fibrillation and chronic kidney disease: a nationwide cohort study
por: Laugesen, Emma Kirstine, et al.
Publicado: (2019)

Economic Evaluation of Warfarin, Dabigatran, Rivaroxaban, and Apixaban for Stroke Prevention in Atrial Fibrillation
por: Wisløff, Torbjørn, et al.
Publicado: (2014)

Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation
por: Yao, Xiaoxi, et al.
Publicado: (2016)

Efficacy and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Asians With Nonvalvular Atrial Fibrillation
por: Chan, Yi‐Hsin, et al.
Publicado: (2018)

Measurement of Anticoagulation in Patients on Dabigatran, Rivaroxaban, and Apixaban Therapy by Novel Automated Thrombelastography
por: Artang, Ramin, et al.
Publicado: (2021)

Effect of government interventions to contain the COVID-19 pandemic on incidence of pulmonary embolism - A Danish nationwide register-based cohort study
por: Sindet-Pedersen, Caroline, et al.
Publicado: (2021)

Risk of atrial fibrillation and stroke in rheumatoid arthritis: Danish nationwide cohort study
por: Lindhardsen, Jesper, et al.
Publicado: (2012)

Stroke Prevention in Atrial Fibrillation: Understanding the New Oral Anticoagulants Dabigatran, Rivaroxaban, and Apixaban
por: Ru San, Tan, et al.
Publicado: (2012)

Comparison of antiplatelet regimens in secondary stroke prevention: a nationwide cohort study
por: Christiansen, Christine Benn, et al.
Publicado: (2015)

Comparative effectiveness of dabigatran, rivaroxaban, apixaban and warfarin in the management of patients with non-valvular atrial fibrillation
por: Pink, Joshua, et al.
Publicado: (2013)

Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Frail Patients With Nonvalvular Atrial Fibrillation
por: Martinez, Brandon K., et al.
Publicado: (2018)

Adherence to Rivaroxaban, Dabigatran, and Apixaban for Stroke Prevention in Incident, Treatment-Naïve Nonvalvular Atrial Fibrillation
por: Brown, Joshua D., et al.
Publicado: (2016)

Comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in atrial fibrillation: a nationwide cohort study
por: Rutherford, Ole-Christian W, et al.
Publicado: (2020)

Outcomes Associated With Familial Versus Nonfamilial Atrial Fibrillation: A Matched Nationwide Cohort Study
por: Gundlund, Anna, et al.
Publicado: (2016)

Stroke and recurrent haemorrhage associated with antithrombotic treatment after gastrointestinal bleeding in patients with atrial fibrillation: nationwide cohort study
por: Staerk, Laila, et al.
Publicado: (2015)

Effects of Apixaban, Rivaroxaban, Dabigatran and Enoxaparin on Histopathology and Laboratory Parameters in Achilles Tendon Injury: An in vivo Study
por: Avci, Sema, et al.
Publicado: (2021)

Risk of incident atrial fibrillation in patients presenting with retinal artery or vein occlusion: a nationwide cohort study
por: Christiansen, Christine Benn, et al.
Publicado: (2018)

Association between biomarkers and COVID-19 severity and mortality: a nationwide Danish cohort study
por: Hodges, Gethin, et al.
Publicado: (2020)

Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis
por: Cohen, A. T., et al.
Publicado: (2015)

Quantification of Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in Human Serum by UHPLC-MS/MS—Method Development, Validation, and Application
por: Lindahl, Sofia, et al.
Publicado: (2018)

Comparative effectiveness of warfarin, dabigatran, rivaroxaban and apixaban in non-valvular atrial fibrillation: A nationwide pharmacoepidemiological study
por: Kjerpeseth, Lars J., et al.
Publicado: (2019)

Analytical verification and comparison of chromogenic assays for dabigatran, rivaroxaban and apixaban determination on BCSXP and STA Compact Max analysers
por: Ćelap, Ivana, et al.
Publicado: (2020)

Evaluation of the DOAC-Stop Procedure by LC-MS/MS Assays for Determining the Residual Activity of Dabigatran, Rivaroxaban, and Apixaban
por: Slavik, L., et al.
Publicado: (2019)

Dabigatran, rivaroxaban, and apixaban are superior to warfarin in Asian patients with non-valvular atrial fibrillation: An updated meta-analysis
por: Li, Wei-Jia, et al.
Publicado: (2021)

Variation in Plasma Levels of Apixaban and Rivaroxaban in Clinical Routine Treatment of Venous Thromboembolism
por: Reda, Sara, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ntvuqcdj5o3u0oira9nalgnsig